Nuwellis Stockholders Approve All Proposals at Special Meeting
Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management, announced that stockholders approved all proposals at their Special Meeting. The key approvals include: warrant exercise authorization for the June 2025 financing, an increase in authorized common stock from 100 million to 200 million shares, and authorization for a potential reverse stock split at a ratio between 1-for-5 and 1-for-70.
The reverse split authorization aims to maintain Nasdaq listing compliance, while the other measures are designed to enhance financial flexibility and support strategic growth initiatives.
Nuwellis (Nasdaq: NUWE), un'azienda di tecnologia medica specializzata nella gestione dei fluidi, ha annunciato che gli azionisti hanno approvato tutte le proposte durante l'Assemblea Straordinaria. Le approvazioni principali includono: l'autorizzazione all'esercizio dei warrant per il finanziamento di giugno 2025, un aumento del capitale sociale autorizzato da 100 milioni a 200 milioni di azioni e l'autorizzazione a un potenziale split azionario inverso con un rapporto compreso tra 1 a 5 e 1 a 70.
L'autorizzazione allo split inverso mira a mantenere la conformità ai requisiti di quotazione Nasdaq, mentre le altre misure sono pensate per aumentare la flessibilità finanziaria e supportare iniziative strategiche di crescita.
Nuwellis (Nasdaq: NUWE), una empresa de tecnología médica especializada en la gestión de fluidos, anunció que los accionistas aprobaron todas las propuestas en su Junta Especial. Las aprobaciones clave incluyen: autorización para el ejercicio de warrants para la financiación de junio de 2025, un aumento del capital social autorizado de 100 millones a 200 millones de acciones, y la autorización para una posible consolidación inversa de acciones en una proporción entre 1 por 5 y 1 por 70.
La autorización para la consolidación inversa tiene como objetivo mantener el cumplimiento con la cotización en Nasdaq, mientras que las otras medidas están diseñadas para mejorar la flexibilidad financiera y apoyar iniciativas estratégicas de crecimiento.
Nuwellis (나스닥: NUWE)는 체액 관리에 특화된 의료기술 회사로, 주주들이 특별회의에서 모든 안건을 승인했다고 발표했습니다. 주요 승인 사항에는 2025년 6월 자금 조달을 위한 워런트 행사 승인, 승인된 보통주 주식 수를 1억 주에서 2억 주로 증가, 그리고 1대 5에서 1대 70 사이의 비율로 역주식 분할 가능성에 대한 승인 등이 포함됩니다.
역주식 분할 승인은 나스닥 상장 요건을 유지하기 위한 것이며, 기타 조치는 재무 유연성을 높이고 전략적 성장 이니셔티브를 지원하기 위해 설계되었습니다.
Nuwellis (Nasdaq : NUWE), une entreprise de technologie médicale spécialisée dans la gestion des fluides, a annoncé que les actionnaires ont approuvé toutes les propositions lors de leur assemblée extraordinaire. Les approbations clés comprennent : l'autorisation d'exercer les bons de souscription pour le financement de juin 2025, une augmentation du capital social autorisé de 100 millions à 200 millions d'actions, et l'autorisation d'une éventuelle fusion inversée d'actions à un ratio compris entre 1 pour 5 et 1 pour 70.
L'autorisation de la fusion inversée vise à maintenir la conformité avec la cotation Nasdaq, tandis que les autres mesures sont conçues pour renforcer la flexibilité financière et soutenir les initiatives stratégiques de croissance.
Nuwellis (Nasdaq: NUWE), ein Medizintechnikunternehmen, das sich auf Flüssigkeitsmanagement spezialisiert hat, gab bekannt, dass die Aktionäre auf ihrer außerordentlichen Hauptversammlung alle Vorschläge genehmigt haben. Zu den wichtigsten Genehmigungen gehören: die Ermächtigung zur Ausübung von Warrants für die Finanzierung im Juni 2025, eine Erhöhung des genehmigten Stammkapitals von 100 Millionen auf 200 Millionen Aktien sowie die Genehmigung einer möglichen Aktienzusammenlegung im Verhältnis von 1:5 bis 1:70.
Die Genehmigung der Aktienzusammenlegung soll die Einhaltung der Nasdaq-Listing-Anforderungen sicherstellen, während die anderen Maßnahmen darauf abzielen, die finanzielle Flexibilität zu erhöhen und strategische Wachstumsinitiativen zu unterstützen.
- None.
- Potential significant share dilution from warrant exercises
- Possible reverse split indicates stock price challenges
- Risk of Nasdaq delisting without implementing reverse split
MINNEAPOLIS , Aug. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced that stockholders approved all proposals presented at the company’s Special Meeting of Stockholders, held virtually earlier today.
Each proposal was designed to enhance the company’s financial flexibility and support ongoing strategic growth. The approved items include:
Warrant Exercise Proposal – Stockholders approved the issuance of shares of common stock pursuant to the exercise of warrants sold in the company’s June 10, 2025 financing, in accordance with Nasdaq Listing Rule 5635(d). This approval enables Nuwellis to fully access the committed capital from the offering.
Authorized Shares Increase Proposal – Stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 100 million to 200 million.
Reverse Split Proposal – Stockholders approved an amendment to the Company’s Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-70, to be enacted at the discretion of the Board of Directors, if necessary, to maintain Nasdaq listing compliance.
“We appreciate the strong support from our stockholders,” said John Erb, Chief Executive Officer of Nuwellis. “These approvals mark important progress toward strengthening our capital position and ensuring we have the flexibility to execute our long-term strategy.”
Final voting results will be included in a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
For more information, visit www.nuwellis.com.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Robert Scott
Chief Financial Officer
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
What proposals did Nuwellis (NUWE) stockholders approve at the August 2025 Special Meeting?
What is the purpose of Nuwellis (NUWE) reverse stock split authorization?
How many authorized shares will Nuwellis (NUWE) have after the increase?
What was the purpose of Nuwellis (NUWE) Special Meeting in August 2025?
